Articles tagged with Lung Cancer
Researchers at the University of Würzburg are developing a new therapy for KEAP1-mutated lung cancer using a sulfite inhibitor to block tumor cell growth. The team has identified a first-of-its-kind compound, SulfExstatin-1, which accumulates toxic sulfite in cancer cells, initiating their death.
A multidisciplinary guideline panel has determined that guided-bronchoscopy sampling provides tissue of comparable adequacy to percutaneous biopsy for comprehensive biomarker testing, while delivering a superior safety profile. Modern navigational bronchoscopy offers a safer path to molecular insights in lung cancer care.
Researchers at Mass General Brigham found that targeted radiation was successful in treating patients with brain metastases, resulting in a lower neurological death rate and reduced need for subsequent whole brain radiation. This study supports personalized treatment approaches to maintain quality of life while managing brain metastases.
A new multi-institutional clinical trial will test zipalertinib, an investigational drug targeting specific EGFR mutations in early-stage non-small cell lung cancer. The goal is to prevent recurrence and improve long-term outcomes for patients with limited treatment options.
A recent analysis of 16 years of data on Japanese adults reveals a strong association between socioeconomic status and the incidence of five common cancers. Communities with low employment rates or low incomes show higher cancer rates compared to those with higher socioeconomic status.
Researchers at Keck Medicine of USC found that high doses of corticosteroids can limit the effectiveness of immunotherapies in treating non-small cell lung cancer. Corticosteroids, commonly prescribed for symptom management, were shown to stop T-cells from maturing, reducing their ability to attack cancer cells.
A whole-genome sequencing study found fine-particulate air pollution to cause more cancer-related changes than secondhand smoke. Researchers analyzed lung tumors from 871 never-smoker patients across 28 geographic locations worldwide and linked air pollution exposure to increased genomic changes.
A new study reveals that air pollution contributes to the development of lung cancer in people with no or hardly any history of smoking. The study found a strong association between air pollution and genetic mutations in lung tumors, particularly driver mutations that promote cancer development.
Residential segregation contributes to lung cancer development in African Americans, highlighting the need for policymakers to address disparities. Structural racism in neighborhoods affects health outcomes, emphasizing the importance of reducing racial gaps in healthcare.
This study identifies pre-neadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) as significant predictors of postoperative recurrence-free survival in non-small cell lung cancer (NSCLC) patients after neoadjuvant therapy. Smoking history is also a predictor of recurrence in LUSC patients.
A new study found diverse genetic patterns and treatment gaps in HER2-mutated non-small cell lung cancer (NSCLC) in Northeastern Brazil. The research highlights the importance of comprehensive molecular profiling and expanded access to targeted therapies for underrepresented populations.
A new dual-phase CT AI tool, NeoPred, combines pre-treatment and pre-surgery scans with clinical data to predict major pathological response in NSCLC patients. The model achieved high accuracy rates, including AUCs of 0.772-0.787, outperforming surgeons and improving diagnostic accuracy.
Researchers found that lung cancer patients with both high levels of depression and inflammation at diagnosis had increasing depressive symptoms over the next eight months. These patients showed no changes in depression when only having high levels of depression or only high levels of inflammation, or neither. The study suggests an add...
A study of 95 patients found that wrapping autologous tissue materials around anastomoses after airway reconstruction significantly reduced short-term postoperative complications. This technique may offer a positive effect on the prognosis of patients undergoing complex tracheobronchial resection and reconstruction.
A retrospective study found ESL to be a safe and viable alternative to pneumonectomy for selected patients with centrally located NSCLC. ESL offered better event-free survival compared to pneumonectomy.
A study of 203 patients shows that electromagnetic navigation bronchoscopy (ENBDM) is a safer and faster alternative to CT-guided localization for preoperative treatment of multiple pulmonary nodules in the same lung. ENBDM achieved comparable accuracy with lower complication rates, making it an optimal strategy.
Researchers developed a tool to monitor treatment response in patients with solid tumours using circulating tumour DNA analysis, anticipating clinical relapses up to 68 months before symptoms become apparent. The technology is minimally invasive and can be tailored to each tumour type, reducing unnecessary treatments and costs.
The addition of perioperative toripalimab to platinum-based chemotherapy has demonstrated significant improvements in disease-related outcomes, including event-free survival and major pathologic response rates. However, this is associated with a small increase in grade 3–5 toxicities and immune-related adverse events.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
Researchers found that cigarette smoke and reduced DNA repair capacity combine to increase cancer risk, with normal lung cells showing extensive damage after smoke exposure. The study's findings support a 'double hit' model, highlighting the critical role of XPC protein in preventing DNA damage.
A revolutionary AI model has been developed to diagnose lung cancer without relying on costly GPU servers or massive datasets. The ultra-lightweight model achieved a discrimination performance corresponding to an AUC value of 0.92, outperforming state-of-the-art large-scale AI systems.
The S2302 Pragmatica-Lung trial found that the investigational combination of ramucirumab and pembrolizumab did not extend overall survival compared to standard-of-care treatments. The study enrolled a highly representative population of patients, establishing it as a paradigm-shifting model for large randomized studies.
DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.
Research reveals NADK tetramer defective mutants enhance tumor progression and chemotherapy resistance by regulating enzyme activity. Mutations impacting tetramer formation suppress activity, while others promote cancer cell growth and sensitivity to chemotherapy.
A new study has launched a novel blood test to identify people of Asian and Hispanic/Latinx descent who are at high risk of lung cancer but have never used tobacco. The trial aims to evaluate the feasibility of screening these individuals for free using CT scans, with the goal of detecting lung cancer at an early stage.
Researchers identified a new biomarker, TTF-1, that predicts survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib. Patients with low TTF-1 levels responded poorly to sotorasib, while those with high TTF-1 levels showed improved outcomes.
The University of Houston has launched a $3M Cancer Immunotherapy Biomarker Core to accelerate early diagnosis and treatment response in cancer. The core will offer comprehensive targeted proteomic cancer biomarker screens, enabling researchers to identify better biomarkers for cancer.
The study evaluated the mutation profiles of lung squamous cell carcinoma (LSCC) detected by next-generation sequencing to assess relationships with clinicopathological parameters. Detection of mutations revealed associations between certain genes, such as PIK3CA and NF1, with specific histopathological features.
Four Weill Cornell Medicine investigators received the Ritu Banga Healthcare Disparities Research Awards to tackle disparities in cancer care, racial and ethnic differences in pediatric Hodgkin lymphoma, and access barriers to high-quality surgical cancer care. The awards support innovative research aimed at improving health outcomes f...
Researchers will present AI models that predict chronic respiratory failure and detect airway obstruction, with key findings on asthma susceptibility, small airway disease, and lung inflammation. The studies use nasal epithelial gene expression analyses and bronchoscopy to identify potential biomarkers for ICU patient outcomes.
A deep learning model called Sybil can predict future lung cancer risk from a single low-dose chest CT scan. The model demonstrated good performance in predicting cancer diagnosis at both one and six years, including in never-smokers.
A nationwide cohort study found that immune checkpoint inhibitors significantly increase the risk of myocarditis in NSCLC patients, with a 7.4-fold increase in risk compared to non-users. Cardiac monitoring for at least six months following ICI initiation is recommended.
Researchers investigated pleurodesis treatment for lung cancer patients with interstitial lung disease, finding an efficacy rate of about 70% with talc and minocycline. However, cases with partially expanded lungs or recent systemic prednisolone treatment increased the risk of acute respiratory distress syndrome.
Researchers found that using current lung cancer screening criteria may overlook at-risk populations, such as older adults and non-English speakers. Incorporating additional factors could enhance diagnostic screening effectiveness in Emergency Department patients.
The study demonstrated the diagnostic utility of endobronchial ultrasound elastography for detecting benign and malignant lymph nodes. The combined index of elastography grading score and short diameter yielded an area under the receiver operating characteristic curve of 0.702, indicating moderate accuracy.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
A new study found that neoadjuvant dual immuno-combination therapy with relatlimab and nivolumab achieved a 93% one-year disease-free survival rate and 100% one-year overall survival rate in patients with resectable non-small cell lung cancer. The therapy also showed promising outcomes, including a pathological complete response rate o...
This study compares laser-guided technology to conventional manual percutaneous lung biopsy, finding that laser-guided technology can reduce operational time and needle adjustments. However, it did not reduce complication rates or improve pathological diagnosis accuracy compared to traditional methods.
The APPLE trial updated investigated the treatment strategy's impact on brain metastasis control and circulating tumour DNA progression-free survival. The study found no significant differences between upfront osimertinib or sequential treatment, but suggested a viable option for regions with first-line osimertinib access issues.
A new study introduces the RAPID-RT study, which uses a rapid-learning approach to evaluate the impact of treatment modifications in radiotherapy. The technique aims to reduce cardiac toxicity and improve survival in lung cancer patients by minimising dose to the top of the heart, a previously identified risk area.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A new study found that pregnancy-related glycoproteins (PSGs) are strongly associated with poorer outcomes in female lung cancer patients. The analysis suggests targeting these genes may improve survival in female patients with lung cancer, and the researchers plan to pursue further investigation into their role.
Researchers have developed three-dimensional spheroid cultures that better replicate cell-cell interactions and nutrient gradients, leading to a greater understanding of tumour tissue behaviour and drug responses. The study highlights the importance of mimicking tumour architecture in testing cancer therapies.
A non-risk-based lung cancer screening approach using low-dose computed tomography (LDCT) in Chinese populations detects a significant number of early-stage lung cancers. The study found that incorporating non-high-risk individuals into screening programs can lead to a greater detection rate and improved patient outcomes.
The phase Ia/Ib Beamion LUNG-1 trial found that zongertinib elicited durable responses in patients with advanced, previously treated non-small cell lung cancer (NSCLC) harboring a HER2 mutation. The disease control rate was high across cohorts, with median progression-free survival ranging from 12.4 to 6.8 months.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
A phase I clinical trial found that zoldonrasib elicited objective responses and disease control in patients with KRAS G12D-mutated NSCLC. The study demonstrated the efficacy and tolerability of the oral agent, which selectively targets the active conformation of KRAS.
A recent study found that cigarette smoking continues to decline across the US, mainly driven by young adults. The states with historically high smoking rates have seen the most significant declines in smoking prevalence.
Researchers found that blood cells carrying age-related mutations can infiltrate tumours, leading to worse cancer outcomes. The presence of these mutations was associated with shorter survival rates in patients with lung and other aggressive cancers.
Liquid biopsy analyzes circulating tumor components in body fluids to detect cancer at early stages, offering a safer and more dynamic alternative to traditional tissue biopsies. This non-invasive approach has shown promise in detecting various types of cancer, including lung, breast, colorectal, prostate, and gastric cancers.
A recent preclinical study from Weill Cornell Medicine researchers suggests that three-dimensional gene hubs may promote brain cancer. The findings, published in Molecular Cell, offer a new way to think about cancer beyond gene mutations and highlight the importance of understanding DNA organization in tumor cells.
Researchers developed an AI algorithm based on the medical history of over half a million patients, enabling GPs to identify increased risk of lung cancer up to 4 months before diagnosis. This method may also offer early detection for other types of cancer and improved patient outcomes.
The Lung-MAP 3.0 trial introduces a simplified genomic screening process, allowing most patients to be matched to a targeted treatment sub-study based on prior testing results. This expansion increases access to investigational treatments for patients with advanced non-small cell lung cancer.
A new study published in The Annals of Thoracic Surgery found that Medicaid expansion significantly improved access to timely treatment for patients with early-stage non-small cell lung cancer. High-volume hospitals associated with decreased postoperative complications and in-hospital mortality rates compared to low-volume hospitals.
A new study suggests that CT scans could account for 5% of all cancer cases each year, primarily due to radiation exposure. The largest risk is among infants, followed by children and adolescents. To mitigate this risk, reducing the number of scans and doses per scan can help save lives.
A study by the University of Barcelona reveals that dynamic BH3 profiling can predict the effectiveness of ALK inhibitors in treating non-small cell lung cancer. The technique helps select the best drug for each patient, overcoming tumour adaptations to inhibitors.
Researchers at KAIST discovered that DDX54 is the master regulator hindering immunotherapy's effectiveness in lung cancer. Supressing DDX54 enhances immune cell infiltration into tumors and improves immunotherapy efficacy.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed in Elsevier's Scopus database. This achievement is a testament to the high-quality research published in these journals, which provide open access content in pulmonary and critical care medicine.